LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 285 -1.70 (-0.59%) (As of 10/28/2024 09:17 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider Trades About MaxCyte Stock (LON:MXCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MaxCyte alerts:Sign Up Key Stats Today's Range 276▼ 29050-Day Range 280▼ 34052-Week Range 231▼ 430Volume16,386 shsAverage Volume23,336 shsMarket Capitalization£299.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock News HeadlinesMaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in StockOctober 4, 2024 | insidertrades.comMaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core ChallengesOctober 10, 2024 | finance.yahoo.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 29, 2024 | Porter & Company (Ad)MaxCyte (NASDAQ:MXCT) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comMaxCyte director Stanley Erck sells shares worth over $178kOctober 4, 2024 | investing.comTD Cowen Reaffirms Their Buy Rating on MaxCyte (MXCT)September 25, 2024 | markets.businessinsider.comMaxCyte and Kamau Therapeutics sign platform license agreementSeptember 17, 2024 | finance.yahoo.comMaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five yearsAugust 21, 2024 | finance.yahoo.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 352.50 at the beginning of the year. Since then, MXCT shares have decreased by 19.1% and is now trading at GBX 285. View the best growth stocks for 2024 here. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryBusiness Services Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-35,430,000.00 Net Margins-77.97% Pretax MarginN/A Return on Equity-15.33% Return on Assets-11.07% Debt Debt-to-Equity Ratio8.37 Current Ratio14.31 Quick Ratio14.38 Sales & Book Value Annual Sales£45.44 million Price / Sales6.59 Cash FlowGBX 144.52 per share Price / Cash Flow1.97 Book ValueGBX 211 per share Price / Book1.35Miscellaneous Outstanding Shares105,090,000Free FloatN/AMarket Cap£299.51 million OptionableNot Optionable Beta1.13 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:MXCT) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.